Richard Pestell

Last updated
Richard G. Pestell
AO FRACP FRCP FRCPI FACP
Dr. Richard Pestell - 2022.png
Born
Perth, Western Australia
Citizenship United States, Australia
Alma mater New York University
University of Melbourne
University of Western Australia
SpouseAnna Pestell
Children3
Awards
Scientific career
Fields Oncology, Endocrinology
InstitutionsHarvard Medical School
Massachusetts General Hospital
Baruch S. Blumberg Institute
Thomas Jefferson University
Georgetown University Medical Center
Albert Einstein College of Medicine

Richard G. Pestell is an Australian American oncologist, endocrinologist and research scientist. Pestell was appointed an Officer of the Order of Australia for distinguished service to medicine and medical education in 2019 by Queen Elizabeth II. [1] He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. He founded six biotechnology companies developing cancer therapy and diagnostics. [2] He is currently Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute. [3]

Contents

Education and early career

A native of Perth, Western Australia, Pestell attended Christ Church Grammar School. He attended the University of Western Australia School of Medicine, receiving his M.B.B.S. [4] He conducted clinical training in internal medicine, oncology and endocrinology. He was awarded the Fellow of the Royal Australian College of Physicians (FRACP) in 1989. [5] He received a Ph.D. in 1991 and M.D. in 1997 from the University of Melbourne. He was the recipient of both the Neal Hamilton Fairley Fellowship, and the Winthrop Fellowship of the Royal Australian College of Physicians. [5] He became a postdoctoral clinical and research fellow in medicine at the Massachusetts General Hospital and a postdoctoral research fellow in medicine at Harvard Medical School in 1991. [6]

Career

Pestell was recruited as an Assistant Professor to the Department of Molecular Medicine at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. He became an Associate Professor and Professor in the Departments of Medicine and Developmental and Molecular Biology at the Albert Einstein College of Medicine in New York. Pestell served as Chair of the Division of Endocrine-Dependent Tumor Biology at the Albert Einstein Cancer Center. [7]

In 2002, Pestell was named Director of the Lombardi Cancer Center, the Francis L. and Charlotte Gragnani Endowed Chair, and Chairman of the Department of Oncology at the Georgetown University Medical Center. [8] During this tenure, he also served as Associate Vice President of the Georgetown University Medical Center, at the Georgetown University School of Medicine. Pestell led the effort for renewal of the National Cancer Institute designation, and supported Dr. Mandelblatt in founding the Capital Breast Care Center with Andrea Jung of the Avon Foundation. [9] In 2003, he was also named President of the US branch of the International Network for Cancer Treatment and Research. [10]

From 2005 to 2015, Pestell was Director of the Sidney Kimmel Cancer Center in Philadelphia, Pennsylvania, and Executive Vice President of Thomas Jefferson University. During his tenure the US News Ranking for the Oncology programs improved from #65 to #17. [11] Pestell expanded the Center to consortium Cancer Center status and led the successful renewals of the National Cancer Institute designation for 10 years. He expanded the Cancer Center network from 13 to 32 sites and founded several centers [12] and international collaborative agreements (Italy, China, Russia, Hungary, Australia)". [13] He was the Founding Director for the Delaware Valley Institute for Clinical and Translational Science. [14] He was called to give testimony to the Committee on Appropriations for the United States Senate in 2009. [15]

Since 2017, Pestell has served as President, Pennsylvania Cancer Center and Regenerative Medicine Center, and Blumberg Distinguished Professor, Translational Medical Research, Baruch S Blumberg Institute. In January 2019, Pestell was named Vice Chairman of the Board of the CytoDyn, Inc., which acquired his prior company, ProstaGene, in November 2018. [16] [17] As the Chief Medical Officer, he established the company's cancer clinical trial for the use of a CCR5 inhibitor (leronlimab) [18] and FDA fast track designation in May 2019. [19] He exited CytoDyn in July 2019 and is currently member of the Wistar Institute Cancer Center Philadelphia and Blumberg Distinguished Professor. [20]

Research

Pestell with Laura Bush, Andrea Jung, and Kathleen Walas of Avon Products, Inc. Jung,Bush,Pestell,Walas.jpg
Pestell with Laura Bush, Andrea Jung, and Kathleen Walas of Avon Products, Inc.

There are more than 96,500 citations to Pestell's work. He has an H-index of 157 and an i10 index 483. [21] [22] He is ranked by Google Scholar for his areas of research including: cell cycle (#1), prostate cancer, Oncology and Breast cancer. [23]

Pestell's research has included contributions to understanding of cancer onset and progression including breast and prostate cancer. [24] Pestell showed that nuclear receptors (estrogen, androgen and PPARγ) are acetylated, and that this event is rate-limiting in hormone signaling and growth control- thus identifying a new target for cancer therapy. His laboratory demonstrated this was a general mechanism conserved among nuclear receptors that affect diverse biological processes. [25]

In the cell cycle field, Pestell's research has shown the discovery that cyclins are direct transcriptional targets of oncogenic and tumour suppressor signals. He showed that cyclin expression is rate-limiting for oncogene-induced breast tumor growth in vivo. His research served as the preclinical reference citation in the IND (investigational new drug) application to the FDA for the initial clinical research programs (palbocicilib, NCT02947685), for what is now the standard of care for the treatment of breast cancer subsets. He has been a pioneer of the non-canonical functions of cyclins and was the first to show that cyclins regulate diverse function including miRNA biogenesis, cellular migration, mitochondrial metabolism (the Warburg effect), angiogenesis and nuclear receptor function and hormone signaling in vivo. [26]

Pestell defined key target genes required for breast cancer stem cell expansion in vivo including p21Cip1, [27] c-Jun, the canonical NF-κB pathway, [28] the cell fate determination pathway protein DACH1, [29] and CCR5. [30]

Pestell discovered CCR5 governs cancer metastasis [31] in both breast and prostate cancer [32] providing the potential for therapeutic targeting [33] [30] with issued patents in this domain. [34] Pestell incorporated these patents into a biotechnology company he had founded (ProstaGene), that was subsequently acquired by CytoDyn. [16] Pestell subsequently initiated the company's currently active cancer treatment clinical trial initiatives targeting CCR5 receiving fast track designation in May 2019. [35]

Pestell is the founder of four biotechnology companies and holds patents in the areas of cancer diagnostics, therapeutics and technologies. [36]

Awards and honors

Personal life

Pestell is married to Anna Pestell and has three children. [37] He is the great-grandson of Albert Green, Minister for Defence under the Scullin Government. [53] son of George Pestell and related to other assorted ancestors. [54]

He was intercollegiate cross country champion, received the HA Craven (best track distance runner), and full blue for athletics (1981) and in 1984, Pestell won the WA State running (5,000 meters track, 10,000 meters road) and walking championships (5,000 m, 20K and 50K). [55]

Selected publications

Related Research Articles

<span class="mw-page-title-main">CCR5</span> Immune system protein

C-C chemokine receptor type 5, also known as CCR5 or CD195, is a protein on the surface of white blood cells that is involved in the immune system as it acts as a receptor for chemokines.

<span class="mw-page-title-main">CCL5</span> Mammalian protein found in humans

Chemokine ligand 5 is a protein which in humans is encoded by the CCL5 gene. The gene has been discovered in 1990 by in situ hybridisation and it is localised on 17q11.2-q12 chromosome.

<span class="mw-page-title-main">Cyclin D1</span> Protein found in humans

Cyclin D1 is a protein that in humans is encoded by the CCND1 gene.

Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.

Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19, triple negative breast cancer, and HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015. In February 2018, Cytodyn Inc reported that the primary endpoint had been achieved in the PRO 140 pivotal combination therapy trial in HIV infection. In 2020 CytoDyn submitted a fast-track biologics license application for treatment of CCR5-tropic HIV-1 Infection.

I. Bernard Weinstein was an American physician and researcher who studied the effect of pollutants and other environmental factors in causing cancer and headed the Comprehensive Cancer Center at Columbia University. He has been credited with helping create the field of molecular epidemiology, which studies how genetic and environmental risk factors are related to the spread of disease in populations.

CCR5 receptor antagonists are a class of small molecules that antagonize the CCR5 receptor. The C-C motif chemokine receptor CCR5 is involved in the process by which HIV, the virus that causes AIDS, enters cells. Hence antagonists of this receptor are entry inhibitors and have potential therapeutic applications in the treatment of HIV infections.

<span class="mw-page-title-main">Brian Druker</span> American physician-scientist

Brian J. Druker, M.D. is a physician-scientist at Oregon Health & Science University (OHSU), in Portland, Oregon. He is the chief executive officer of OHSU's Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Associate Dean for Oncology in the OHSU School of Medicine, and professor of medicine.

Wafik El-Deiry is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Brown University, Director of the Cancer Center at Brown University, and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously deputy director of Translational Research at Fox Chase Cancer Center, where he was also co-Leader of the Molecular Therapeutics Program.

<span class="mw-page-title-main">David Gorski</span> Science-based medicine advocate

David Henry Gorski is an American surgical oncologist and professor of surgery at Wayne State University School of Medicine. He specializes in breast cancer surgery at the Karmanos Cancer Institute. Gorski is an outspoken skeptic and critic of alternative medicine and the anti-vaccination movement. He writes as Orac at Respectful Insolence and as himself at Science-Based Medicine, where he is the managing editor.

<span class="mw-page-title-main">Palbociclib</span> Medication for HR+ HER2− breast cancer

Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.

Ralph R. Weichselbaum is an American physician specializing in radiation oncology, a member of the Institute of Medicine of the National Academy of Sciences, Ludwig professor, He is Daniel K. Ludwig Distinguished Service Professor of Radiation Oncology and Chairman, Department of Radiation and Cellular Oncology, at the University of Chicago Pritzker School of Medicine, and Head of the University of Chicago Center for Radiation Therapy, and the director of the Chicago Tumor Institute. Weichselbaum is also Co- Director of the Ludwig Center for Metastasis Research at the University of Chicago.

Serdar Bulun is a gynecologist, with a special interest in the common gynecologic diseases, endometriosis and uterine fibroids.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

Michael A. Caligiuri is an American physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. He was elected to the United States National Academy of Medicine in 2018.

Shyam Swarup Agarwal was an Indian geneticist, immunologist and the director of Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI-MS), Lucknow. A former director of the Advanced Center for Treatment, Research and Education in Cancer (ACTREC) at the Tata Memorial Centre, he was the pioneer of medical genetics and clinical immunology education in India. Known for his researches in the fields of genetics and molecular biology, he was an Emeritus Professor of the National Academy of Medical Sciences, and an elected fellow of all the three major Indian science academies, namely, the Indian Academy of Sciences, National Academy of Sciences, India, and the Indian National Science Academy. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Medical Sciences in 1986.

Andrew Louis Pecora is an American hematologist and oncologist involved in research on the use of stem cells and oncolytic viruses to treat diseases, including cancer. He is the CEO of Outcomes Matter Innovations. As of 2020, he is on the Board of Directors Celularity, Inc. (since 2017) and founder and Executive Chairman, COTA, Inc.. Previously, he was chief innovations officer, professor and vice president of cancer services at the John Theurer Cancer Center, part of the Hackensack University Medical Center. He is a professor of medicine and oncology at Georgetown University.

<span class="mw-page-title-main">University of Western Australia School of Medicine</span> Medical school in Western Australia

The University of Western Australia Medical School is the medical school of The University of Western Australia, located in Perth, Western Australia. Established in 1957, it is the oldest medical school in Western Australia, with over 6000 alumni. Well known for its research and clinical teaching, the medical school is ranked 8th in the world and 1st in Australia by the 2019 Academic Ranking of World Universities in clinical medicine. The medical school is affiliated with various teaching hospitals in Perth such as Royal Perth Hospital and Sir Charles Gairdner Hospital. The medical school is also heavily affiliated with the Queen Elizabeth II Medical Centre and its various research institutes. The school has prominent researchers and clinicians amongst its faculty and alumni, including Nobel Prize laureates Barry Marshall and Robin Warren ; recipients of the Australian of the Year award Fiona Stanley and Fiona Wood; and cancer researcher Richard Pestell. The school has produced 11 Rhodes Scholars.

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.

<span class="mw-page-title-main">Richard James Cote</span> Pathologist

Richard James Cote is a pathologist, academic and author. He is the Edward Mallinckrodt Professor and Chair of the Department of Pathology and Immunology at Washington University in St. Louis School of Medicine, and the Pathologist-in-Chief at Barnes Jewish Hospital.

References

  1. 1 2 "Professor Richard George Pestell". honours.pmc.gov.au. Retrieved 2019-06-10.
  2. ↑ "Richard Pestell" . Retrieved 2024-05-05.
  3. ↑ "World-renowned cancer physician scientist Dr Richard Pestell joins the Baruch S. Blumberg Institute". Advance. Retrieved 2018-07-11.
  4. ↑ "UWA alumni named Australia's most innovative global leaders". News | The University Of Western Australia. Retrieved 2019-01-24.
  5. 1 2 "BCRF :: Richard G. Pestell, MB, BS, PhD, MD, FACP". legacy.bcrfcure.org. Archived from the original on 2016-03-20. Retrieved 2018-07-11.
  6. ↑ Pestell, R. (2006). "Remembering team science is for the patients". Cancer Biology & Therapy. 5 (4): 449–52. doi: 10.4161/cbt.5.4.2563 . PMID   16575209.
  7. 1 2 "Noted Georgetown Physician-Scientist Richard G. Pestell, M.D., Ph.D., Named Director Of The Kimmel Cancer Center At Jefferson" . Retrieved 2005-11-03.
  8. ↑ "CANCER CENTER SUPPORT GRANT: Project Number 3P30CA051008-16S6" . Retrieved 2024-05-05.
  9. ↑ "Professor Richard George Pestell : Faculty of Medicine, Dentistry and Health Sciences". Faculty of Medicine, Dentistry and Health Sciences. 2016-11-24. Retrieved 2018-07-11.
  10. ↑ "Richard Pestell". Advance. Retrieved 2019-01-22.
  11. ↑ https://www.jefferson.edu/content/dam/tju/JeffNews/documents/2013/JeffNEWS_Aug_Oct_2013.pdf [ bare URL PDF ]
  12. ↑ "Sidney Kimmel Cancer Center : Center to Eliminate Cancer Disparities".
  13. ↑ "2015 Sidney Kimmel Cancer Center Report". Jul 22, 2015. Retrieved 2024-05-05.
  14. ↑ Fioritti, Nathan (2016-11-24). "Professor Richard George Pestell". Faculty of Medicine, Dentistry and Health Sciences. Retrieved 2019-01-22.
  15. ↑ "govinfo". www.govinfo.gov. Retrieved 2019-01-22.
  16. 1 2 "CytoDyn Signs Definitive Agreement to Acquire ProstaGene; Founder and CEO Dr. Richard Pestell to Join CytoDyn as Interim Chief Medical Officer".
  17. ↑ "CytoDyn Completes Acquisition of ProstaGene and Names Dr. Richard G. Pestell to Board of Directors".
  18. ↑ https://www.globenewswire.com/news-release/2018/11/05/1644858/19782/en/CytoDyn-Files-IND-and-Protocol-for-Phase-1b-2-Clinical-Trial-in-Metastatic-Triple-Negative-Breast-Cancer-with-PRO-140-Leronlimab.html) Archived 2021-07-19 at the Wayback Machine
  19. ↑ "FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need" (Press release). 7 May 2019.
  20. ↑ "Richard G. Pestell, MD, PhD, FACP, FRACP, MBA".
  21. ↑ "Richard Pestell" . Retrieved 2023-01-15.
  22. ↑ "Highly Cited Researchers (H>100) according to their Google Scholar Citations public profiles | Ranking Web of Universities: Webometrics ranks 30000 institutions".
  23. ↑ "Richard Pestell".
  24. ↑ "Professor Richard George Pestell : Faculty of Medicine, Dentistry and Health Sciences". Faculty of Medicine, Dentistry and Health Sciences. 2016-11-24. Retrieved 2018-07-13.
  25. 1 2 "The Endocrine Society of Australia -". www.endocrinesociety.org.au. Retrieved 2019-02-07.
  26. ↑ Fioritti, Nathan (2016-11-24). "Professor Richard George Pestell". Faculty of Medicine, Dentistry and Health Sciences. Retrieved 2019-02-07.
  27. ↑ Liu, Manran; Casimiro, Mathew C.; Wang, Chenguang; Shirley, L. Andrew; Jiao, Xuanmao; Katiyar, Sanjay; Ju, Xiaoming; Li, Zhiping; Yu, Zuoren (2009-11-10). "p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo". Proceedings of the National Academy of Sciences of the United States of America. 106 (45): 19035–19039. Bibcode:2009PNAS..10619035L. doi: 10.1073/pnas.0910009106 . ISSN   1091-6490. PMC   2776463 . PMID   19858489.
  28. ↑ Liu, Manran; Sakamaki, Toshiyuki; Casimiro, Mathew C.; Willmarth, Nicole E.; Quong, Andrew A.; Ju, Xiaoming; Ojeifo, John; Jiao, Xuanmao; Yeow, Wen-Shuz (2010-12-15). "The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion". Cancer Research. 70 (24): 10464–10473. doi:10.1158/0008-5472.CAN-10-0732. ISSN   1538-7445. PMC   3010731 . PMID   21159656.
  29. ↑ Puntarić, D.; Hebrang, A. (September 1990). "[Analysis of the frequency, types and justification for radiographic examination based on a sample of a community population]". Lijecnicki Vjesnik. 112 (9–10): 288–293. ISSN   0024-3477. PMID   2093783.
  30. 1 2 Jiao, Xuanmao; Velasco-Velázquez, Marco A.; Wang, Min; Li, Zhiping; Rui, Hallgeir; Peck, Amy R.; Korkola, James E.; Chen, Xuelian; Xu, Shaohua (2018-04-01). "CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion". Cancer Research. 78 (7): 1657–1671. doi:10.1158/0008-5472.CAN-17-0915. ISSN   1538-7445. PMC   6331183 . PMID   29358169.
  31. ↑ Velasco-Velázquez, Marco; Jiao, Xuanmao; De La Fuente, Marisol; Pestell, Timothy G.; Ertel, Adam; Lisanti, Michael P.; Pestell, Richard G. (2012-08-01). "CCR5 antagonist blocks metastasis of basal breast cancer cells". Cancer Research. 72 (15): 3839–3850. doi: 10.1158/0008-5472.CAN-11-3917 . ISSN   1538-7445. PMID   22637726.
  32. ↑ Sicoli, Daniela; Jiao, Xuanmao; Ju, Xiaoming; Velasco-Velazquez, Marco; Ertel, Adam; Addya, Sankar; Li, Zhiping; Andò, Sebastiano; Fatatis, Alessandro (2014-12-01). "CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines". Cancer Research. 74 (23): 7103–7114. doi:10.1158/0008-5472.CAN-14-0612. ISSN   1538-7445. PMC   4294544 . PMID   25452256.
  33. ↑ Velasco-Velázquez, Marco; Pestell, Richard G. (2013-04-01). "The CCL5/CCR5 axis promotes metastasis in basal breast cancer". Oncoimmunology. 2 (4): e23660. doi:10.4161/onci.23660. ISSN   2162-4011. PMC   3654591 . PMID   23734321.
  34. ↑ "Richard G. Pestell Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2019-02-20.
  35. ↑ "Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC". clinicaltrials.gov. Retrieved 2019-02-19.
  36. ↑ "Richard G. Pestell Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2018-07-13.
  37. 1 2 3 4 5 6 7 8 "International Members".
  38. ↑ "Richard Pestell, M.D. Ph.D, FRACP". Life Science Advisors in the USA. Advance. Archived from the original on 2011-07-16. Retrieved 2011-12-29.
  39. ↑ Member profile, American Society for Clinical Investigation. Accessed June 11, 2011 Archived February 15, 2012, at the Wayback Machine
  40. ↑ Mark D'Amico; Kongming Wu; Maofu Fu; Mahadev Rao; Chris Albanese; Robert G. Russell; Hanzhou Lian; David Bregman; Michael White (June 15, 2004). "The Inhibitor of Cyclin-Dependent Kinase 4a/Alternative Reading Frame (INK4a/ARF) Locus Encoded Proteins p16INK4a and p19ARF Repress Cyclin D1 Transcription through Distinct cis Elements". Cancer Research. 64 (12): 4122–4130. doi: 10.1158/0008-5472.can-03-2519 . PMID   15205322 . Retrieved April 26, 2011.
  41. 1 2 3 4 5 "Richard G. Pestell, MD, PhD". Research in Action. The Breast Cancer Research Foundation.
  42. ↑ "Biotech Science News: Richard G. Pestell". Biotech Science News. Retrieved April 26, 2011.
  43. ↑ "Annual Report 2008-2009" (PDF). Welcome New Fellows. College of Physicians of Philadelphia. Archived from the original (PDF) on May 14, 2012.
  44. ↑ "AAAS Members Elected as Fellows in 2011". Fellows. American Association for the Advance of Science. Archived from the original on January 13, 2012.
  45. ↑ "Biotechnology Award: Dr Richard Pestell". Special Broadcasting Service.
  46. ↑ Physicians, The Royal Australasian College of, The Royal Australasian College of Physicians, The Royal Australasian College of Physicians, retrieved 2019-01-23
  47. ↑ "Professor Richard George Pestell". mdhs.unimelb.edu.au. 24 November 2016.
  48. ↑ "Jefferson 2016 NAI Induction.mp4". players.brightcove.net/3303963089001/default_default/index.html?videoId=5071296461001.
  49. ↑ "Komen Philadelphia hosted its More Than Pink Party Distributes Funding". phillychitchat.com/tag/susan-komen/. 24 March 2017. Retrieved 2017-03-24.
  50. ↑ "Blumberg Institute Faculty News". www.blumberginstitute.org/news/blumberg-institute-faculty-news/. 7 December 2022. Retrieved 2023-01-15.
  51. ↑ "Richard Pestell".
  52. ↑ "Academy of Europe: List of Members".
  53. ↑ "Richard G. Pestell, AO., MD, Ph.D., MBA., FACP., FRACP., Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who's Who". www.24-7pressrelease.com/#. Retrieved 2020-03-16.
  54. ↑ "Pestell, George Stanley (1921 - 2002)".
  55. ↑ Wieland, James Murray (2012). The Fat Man's Odyssey: A History of the University of Western Australia Athletic Club. Friends of the UWA Athletic Club. ISBN   9780646580951.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.